Yuejin Li1, Guangshuo Zhu1, Nazareno Paolocci1, Pingbo Zhang1, Cyrus Takahashi1, Nazli Okumus1, Amir Heravi1, Gizem Keceli1, Genaro Ramirez-Correa1, David A Kass1, Anne M Murphy2. 1. From the Division of Cardiology, Department of Pediatrics (Y.L., N.O., A.H., G.R.-C., A.M.M.), Division of Cardiology, Department of Medicine (G.Z., N.P., C.T., G.K., D.A.K.), Department of Pharmacology and Molecular Sciences, Department of Biomedical Engineering (D.A.K.), and Deparment of Ophthalmology (P.Z.), Johns Hopkins University, Baltimore, MD; and Istanbul Faculty of Medicine, Istanbul University, Turkey (N.O.). 2. From the Division of Cardiology, Department of Pediatrics (Y.L., N.O., A.H., G.R.-C., A.M.M.), Division of Cardiology, Department of Medicine (G.Z., N.P., C.T., G.K., D.A.K.), Department of Pharmacology and Molecular Sciences, Department of Biomedical Engineering (D.A.K.), and Deparment of Ophthalmology (P.Z.), Johns Hopkins University, Baltimore, MD; and Istanbul Faculty of Medicine, Istanbul University, Turkey (N.O.). murphy@jhmi.edu.
Abstract
BACKGROUND: In human heart failure, Ser199 (equivalent to Ser200 in mouse) of cTnI (cardiac troponin I) is significantly hyperphosphorylated, and in vitro studies suggest that it enhances myofilament calcium sensitivity and alters calpain-mediated cTnI proteolysis. However, how its hyperphosphorylation affects cardiac function in vivo remains unknown. METHODS AND RESULTS: To address the question, 2 transgenic mouse models were generated: a phospho-mimetic cTnIS200D and a phospho-silenced cTnIS200A, each driven by the cardiomyocyte-specific α-myosin heavy chain promoter. Cardiac structure assessed by echocardiography and histology was normal in both transgenic models compared with littermate controls (n=5). Baseline in vivo hemodynamics and isolated muscle studies showed that cTnIS200D significantly prolonged relaxation and lowered left ventricular peak filling rate, whereas ejection fraction and force development were normal (n=5). However, with increased heart rate or β-adrenergic stimulation, cTnIS200D mice had less enhanced ejection fraction or force development versus controls, whereas relaxation improved similarly to controls (n=5). By contrast, cTnIS200A was functionally normal both at baseline and under the physiological stresses. To test whether either mutation impacted cardiac response to ischemic stress, isolated hearts were subjected to ischemia/reperfusion. cTnIS200D were protected, recovering 88±8% of contractile function versus 35±15% in littermate controls and 28±8% in cTnIS200A (n=5). This was associated with less cTnI proteolysis in cTnIS200D hearts. CONCLUSIONS: Hyperphosphorylation of this serine in cTnI C terminus impacts heart function by depressing diastolic function at baseline and limiting systolic reserve under physiological stresses. However, paradoxically, it preserves heart function after ischemia/reperfusion injury, potentially by decreasing proteolysis of cTnI.
BACKGROUND: In humanheart failure, Ser199 (equivalent to Ser200 in mouse) of cTnI (cardiac troponin I) is significantly hyperphosphorylated, and in vitro studies suggest that it enhances myofilament calcium sensitivity and alters calpain-mediated cTnI proteolysis. However, how its hyperphosphorylation affects cardiac function in vivo remains unknown. METHODS AND RESULTS: To address the question, 2 transgenicmouse models were generated: a phospho-mimetic cTnIS200D and a phospho-silenced cTnIS200A, each driven by the cardiomyocyte-specific α-myosin heavy chain promoter. Cardiac structure assessed by echocardiography and histology was normal in both transgenic models compared with littermate controls (n=5). Baseline in vivo hemodynamics and isolated muscle studies showed that cTnIS200D significantly prolonged relaxation and lowered left ventricular peak filling rate, whereas ejection fraction and force development were normal (n=5). However, with increased heart rate or β-adrenergic stimulation, cTnIS200Dmice had less enhanced ejection fraction or force development versus controls, whereas relaxation improved similarly to controls (n=5). By contrast, cTnIS200A was functionally normal both at baseline and under the physiological stresses. To test whether either mutation impacted cardiac response to ischemic stress, isolated hearts were subjected to ischemia/reperfusion. cTnIS200D were protected, recovering 88±8% of contractile function versus 35±15% in littermate controls and 28±8% in cTnIS200A (n=5). This was associated with less cTnI proteolysis in cTnIS200D hearts. CONCLUSIONS: Hyperphosphorylation of this serine in cTnIC terminus impacts heart function by depressing diastolic function at baseline and limiting systolic reserve under physiological stresses. However, paradoxically, it preserves heart function after ischemia/reperfusion injury, potentially by decreasing proteolysis of cTnI.
Authors: F Di Lisa; R De Tullio; F Salamino; R Barbato; E Melloni; N Siliprandi; S Schiaffino; S Pontremoli Journal: Biochem J Date: 1995-05-15 Impact factor: 3.857
Authors: Pingbo Zhang; Jonathan A Kirk; Weihua Ji; Cristobal G dos Remedios; David A Kass; Jennifer E Van Eyk; Anne M Murphy Journal: Circulation Date: 2012-09-12 Impact factor: 29.690
Authors: Genaro A Ramirez-Correa; Aisha H Frazier; Guangshuo Zhu; Pingbo Zhang; Thomas Rappold; Viola Kooij; Djahida Bedja; Greg A Snyder; Nahyr S Lugo-Fagundo; Raena Hariharan; Yuejin Li; Xiaoxu Shen; Wei Dong Gao; Oscar H Cingolani; Eiki Takimoto; D Brian Foster; Anne M Murphy Journal: J Appl Physiol (1985) Date: 2014-10-16
Authors: Eiki Takimoto; David G Soergel; Paul M L Janssen; Linda B Stull; David A Kass; Anne M Murphy Journal: Circ Res Date: 2004-01-15 Impact factor: 17.367
Authors: Agnieszka Galińska; Victoria Hatch; Roger Craig; Anne M Murphy; Jennifer E Van Eyk; C-L Albert Wang; William Lehman; D Brian Foster Journal: Circ Res Date: 2009-12-24 Impact factor: 17.367